Ace Therapeutics has a dedicated team in the field of liver-targeted drug delivery system development. We have extensive hands-on experience and scientific solutions for various problems. Our excellent team of experts and advanced technology platform support us to provide the most suitable help and support for your research projects.
There are two main pathways for targeting the liver to develop drug delivery systems. One is passive targeting that relies primarily on the mononuclear phagocyte system (MPS) in vivo, and the other is active targeting that includes hepatic parenchymal cell targeting, non-parenchymal cell targeting, and hepatic tumor cell targeting. Different delivery pathways have different uses. We offer unique services for different delivery routes to meet the needs of different research projects.
What Can We Do?
Liver-Targeted Drug Delivery System Development
Accurate delivery of oligonucleotide drugs to the damaged areas of the liver enables them to achieve the most optimal effect. To further enhance the effectiveness of oligonucleotides in the treatment of liver disease, we offer a comprehensive range of oligonucleotide-specific drug delivery services.
- Passive Targeted Liver Drug Delivery System Development
Some specific substances entering the body are rapidly cleared by MPS and accumulate in the liver and other organs, leading to the accumulation of large amounts of drugs at Kupffer cells, which facilitates the treatment of liver inflammation and liver fibrosis. Ace Therapeutics has extensive experience in passively targeted agents and our technologies cover liposomes, microspheres, nanocapsules, and nanospheres. We can provide the most professional and comprehensive research services to our clients in the field of hepatitis and liver fibrosis-related research.
- Active Targeted Liver Drug Delivery System Development
Ace Therapeutics has established unique and well-established service processes for three different delivery pathways that actively target the liver, designed to facilitate the smooth conduct of your research project.
- Drug Delivery System Targeting Hepatic Parenchymal Cells
Desialic acid glycoprotein receptor-mediated liver-targeted drug delivery system Most widely used, hepatic targeting, focused on hepatitis and hepatocellular carcinoma
Glycyrrhetinic acid / glycyrrhetinic acid receptor-mediated targeted drug delivery system Specific targeting of liver lesions
Bile acid salt-mediated liver-targeted drug delivery system Hepatic targeting, less toxic side effects, higher oral bioavailability
- Drug Delivery System Targeting Liver Non-Parenchymal Cells
Mannose receptor-mediated liver-targeted drug delivery system
Mannose-6-phosphate/insulin-like growth factor-mediated liver-targeted drug delivery system
Hyaluronic acid-mediated liver-targeted drug delivery system
- Drug Delivery System Targeting Liver Tumor Cells
Antibody-mediated liver-targeted drug delivery system
Transferrin receptor-mediated liver-targeted drug delivery system
Folate receptor-mediated liver-targeted drug delivery system
Low-density lipoprotein-mediated liver-targeted drug delivery system
Based on our advanced technology and well-established knowledge system, Ace Therapeutics has established a series of methods to facilitate the development of liver-targeted drug delivery systems. If you would like to learn more about our services, please feel free to contact us.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
